ASX:Live
Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Valuation
Value
Consensus
Momentum
Price
Neutral
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.8.6558.0886
Address
Level 3 101 St George’s Terrace Perth, Western Australia (WA) 6000
Description
Zelira Therapeutics Ltd. is a bio-pharmaceutical company. The firm engages in the research and development of cannabinoid-based formulations for the treatment of a variety of medical conditions. It focuses on human clinical trial program and pre-clinical research program. The company was founded by Harry Karelis, Mara Gordon, Jason Peterson, and Stewart Washer on February 18, 2003 and is headquartered in Perth, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.28 - 1.09
Trade Value (12mth)
AU$894.00
1 week
-1.64%
1 month
-14.29%
YTD
-36.17%
1 year
-34.78%
All time high
20453.10
EPS 3 yr Growth
150.20%
EBITDA Margin
%
Operating Cashflow
-$4m
Free Cash Flow Return
-31.60%
ROIC
-263.70%
Interest Coverage
-7.70
Quick Ratio
0.40
Shares on Issue (Fully Dilluted)
11m
HALO Sector
Healthcare
Next Company Report Date
N/A
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
| Date | Announcements |
|---|---|
|
20 November 24 |
Zelira to present at Automic Invest 2024 conference
×
Zelira to present at Automic Invest 2024 conference |
|
14 November 24 |
2024 Annual General Meeting Presentation
×
2024 Annual General Meeting Presentation |
|
14 November 24 |
Results of Meeting
×
Results of Meeting |
|
14 November 24 |
Proposed issue of securities - ZLD
×
Proposed issue of securities - ZLD |
|
29 October 24 |
September 2024 Quarterly Activities Report
×
September 2024 Quarterly Activities Report |
|
29 October 24 |
Appendix 4C Cash Flow Report
×
Appendix 4C Cash Flow Report |
|
11 October 24 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
|
11 October 24 |
Letter to Shareholders
×
Letter to Shareholders |
|
20 September 24 |
Investor Webinar - HOPE FDA Program Update
×
Investor Webinar - HOPE FDA Program Update |
|
18 September 24 |
Notice of Investor Webinar - HOPE FDA Program Update
×
Notice of Investor Webinar - HOPE FDA Program Update |
|
12 September 24 |
AGM Date and Closing Date for Director Nominations
×
AGM Date and Closing Date for Director Nominations |
|
28 August 24 |
Appendix 4E and Financial Report to Shareholders
×
Appendix 4E and Financial Report to Shareholders |
|
28 August 24 |
Appendix 4G
×
Appendix 4G |
|
22 August 24 |
Zelira Receives Positive FDA Minutes from Pre-IND Meeting
×
Zelira Receives Positive FDA Minutes from Pre-IND Meeting |
|
30 July 24 |
June 2024 Quarterly Activities Report
×
June 2024 Quarterly Activities Report |
|
30 July 24 |
Appendix 4C Cash Flow Report
×
Appendix 4C Cash Flow Report |
|
16 July 24 |
Zelira secures leading patents for HOPE 1 and HOPE 2
×
Zelira secures leading patents for HOPE 1 and HOPE 2 |
|
11 July 24 |
ZLD Advances HOPE Autism Drug Program with U.S FDA Meeting
×
ZLD Advances HOPE Autism Drug Program with U.S FDA Meeting |
|
04 July 24 |
Zelira Receives USD$1.4Million Unsecured Loan from Chairman
×
Zelira Receives USD$1.4Million Unsecured Loan from Chairman |
|
01 July 24 |
ZLD secures US$1.4M unsecured Chairman loan facility
×
ZLD secures US$1.4M unsecured Chairman loan facility |
|
23 May 24 |
HOPE SPV receives US$681,000 third tranche of funding
×
HOPE SPV receives US$681,000 third tranche of funding |
|
29 April 24 |
March 2024 Quarterly Activities Report
×
March 2024 Quarterly Activities Report |
|
29 April 24 |
Appendix 4C Cash Flow Report
×
Appendix 4C Cash Flow Report |
|
15 April 24 |
Zelira receives $919,000 R&D Tax Incentive Scheme Refund
×
Zelira receives $919,000 R&D Tax Incentive Scheme Refund |
|
22 February 24 |
Appendix 4D & FY24 Interim Financial Report
×
Appendix 4D & FY24 Interim Financial Report |
Load More
Load Less
Ex Dividend Date (est.)
DIV Yield
Franking Level
DPSg
Quality Yield
Falling Divs over next 2
Consensus Score
Recommendation
EPS 1 month Change
Quality Yield
Falling Divs over next 2
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
.svg)
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.
